期刊文献+

冠心病患者冠状动脉病变进展的相关危险因素的研究 被引量:36

Risk factors related to coronary lesion progress in patients with coronary heart disease
下载PDF
导出
摘要 目的探讨影响初发冠状动脉粥样硬化性心脏病(冠心病)患者冠状动脉病变进展的相关危险因素。方法纳入2008年1月至2012年12月在北京电力医院心内科行冠脉造影检查(CAG)的患者122例,所有患者初次行CAG检查时被确诊为冠心病,在此期间完成第2次CAG检查。根据两次CAG检查结果将患者分为冠脉病变进展组和无进展组。比较两组患者基线时的冠心病相关危险因素包括性别、年龄、吸烟史、高血压病史、糖尿病病史、血脂水平和冠脉病变的特点,采用二分类logistic回归分析研究冠脉病变进展的独立预测因素。结果两次冠脉造影检查平均间隔时间为(33.4±19.5)个月。第2次冠脉造影检查时71例(58.2%)患者有冠脉病变进展,51例(41.8%)患者无冠脉病变进展。与无进展组患者相比,进展组患者基线吸烟者比例更高(59.2%vs.39.2%,P=0.03),基线高密度脂蛋白胆固醇(HDL-C)水平较低(0.97±0.25 mmoL/L vs.1.18±0.25 mmoL/L,P=0.029),基线冠脉造影三支病变者更多(38.0%vs.15.7%,P=0.007),更多患者基线冠脉造影检查时行经皮冠状动脉介入(PCI)治疗(88.7%vs.70.6%,P=0.011)。二分类logistic回归分析显示,基线HDL-C水平(OR=0.167,95%CI:0.033~0.854,P=0.032),基线冠脉造影检查时接受PCI治疗(OR=3.281,95%CI:1.268~8.491,P=0.014),基线时冠脉三支病变(OR=4.289,95%CI:1.447~12.712,P=0.009)和两次冠脉造影检查间隔时间(OR=1.029,95%CI:1.007~1.052,P=0.01)是冠脉病变进展的独立预测因素。结论基线HDL-C水平、基线冠脉造影时接受PCI治疗、三支病变和两次冠脉造影检查间隔时间是冠心病进展的独立预测因素。 Objective To discuss the risk factors related to coronary lesion progress in the patients with coronary heart disease (CHD). Methods The patients (n=122) with coronary angiography (CAG) examinations were chosen from Jan. 2008 to Dec. 2012, and all patients were diagnosed with CHD in the first CAG and they were given the second CAG. All patients were divided into progress group and non-progress group according to the outcomes of 2 times of CAG. The baseline risk factors related to CHD were compared between 2 groups including sex, age, smoking history, hypertension history, diabetes history, level of blood fat and features of coronary lesion. The independent predictors of coronary lesion progress were studied by using binary logistic regression analysis. Results The mean interval was (33.4±19.5) between 2 times of CAG. In the second CAG there were 71 patients (58.2%) with coronary lesion progress and 51 (41.8%) without coronary lesion progress. Compared with non-progress group, the percentage of baseline smoking patients was higher (59.2%vs. 39.2%, P=0.03), baseline level of high-density lipoprotein-cholesterol (HDL-C) was lower (0.97±0.25 mmoL/L vs. 1.18±0.25 mmoL/L, P=0.029), more patients had 3-vessel lesion during baseline CAG (38.0%vs. 15.7%, P=0.007), and more patients had percutaneous coronary intervention (PCI) during baseline CAG (88.7%vs. 70.6%, P=0.011) in progress group. The binary logistic regression analysis showed that baseline HDL-C level (OR=0.167, 95%CI: 0.033-0.854, P=0.032), PCI during baseline CAG (OR=3.281, 95%CI:1.268-8.491, P=0.014), 3-vessel lesion during baseline CAG (OR=4.289, 95%CI:1.447-12.712, P=0.009) and mean interval between 2 times of CAG (OR=1.029, 95%CI:1.007-1.052, P=0.01) were the independent predictors of coronary lesion progress. Conclusion The baseline HDL-C level, PCI during baseline CAG, 3-vessel lesion during baseline CAG and mean interval between 2 times of CAG are the independent predictors of coronary lesion progress.
出处 《中国循证心血管医学杂志》 2014年第3期274-277,共4页 Chinese Journal of Evidence-Based Cardiovascular Medicine
基金 辽宁省科学技术基金项目(2009225010-18)
关键词 冠状动脉疾病 高密度脂蛋白胆固醇 经皮冠状动脉介入治疗 Coronary heart disease High-density lipoprotein-cholesterol Percutaneous coronary intervention
  • 相关文献

参考文献4

二级参考文献46

  • 1叶辉,严江涛,邵娇梅,张帆,洪茂林,汪道文.血浆同型半胱氨酸水平及亚甲基四氢叶酸还原酶基因突变与脑卒中关系的病例对照研究[J].中华流行病学杂志,2004,25(11):958-961. 被引量:32
  • 2叶辉,邵娇梅,蒋键刚,赵春霞,张帆,汪道文.血同型半胱氨酸与心脑血管疾病关系随访研究[J].心脏杂志,2006,18(1):60-61. 被引量:31
  • 3余兴,艾新忠,赵细元.辛伐他汀治疗急性冠状动脉综合征的临床疗效观察[J].中国现代医学杂志,2007,17(4):498-500. 被引量:8
  • 4Shao B, Heinecke JW. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway [ J]. J Proteomics, 2011 Apr 9 [ Epub ahead of print].
  • 5Francis GA. The complexity of HDL [ J]. Biochim Biophys Acta, 2010.1801 (12) :1286-1293.
  • 6Shao B, Oda MN, Oram JF, et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein [ J ]. Chem Res Toxicol, 2010,23 (3) :447-454.
  • 7Holzer M, Gauster M, Pfeifer T, et al. Protein carbamylation renders high-density lipoprotein dysfunetional [ J ]. Antioxid Redox Signal, 2011,14(12) :2337-2346.
  • 8Sirpal S. Myeloperoxidase-mediated lipoprotein earbamylation as a mechanistic pathway for atherosclerotic vascular disease [ J ]. Clin Sci, 2009,116(9) :681-695.
  • 9Schindhelm RK, van der Zwan LP, Teerlink T, et al. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification [J]. Clin Chem, 2009,55(8) :1462-1470.
  • 10Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease [J]. J CIin Invest, 2011,121 (7) :2693- 2708.

共引文献370

同被引文献399

引证文献36

二级引证文献313

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部